Navigation Links
NHS reforms not benefiting patients

Although the new government health refoms have cost millions of pounds to the NHS, they seem to have proved to be of very little benefit for the patients//.

Cosultants pay and pension have been increased in the NHS but the King’s fund report state that there is no difference to patient care.

This has put a lot of pressure on the budgets of the hospitals. There has been no planning and no guidance on this. Many have seen these contracts as 'a box to be ticked' making it a very costly exercise.

Consultants have been asked to work for an extra four hours every week for the NHS, on the assumption that they would give more attention to the NHS before their private practice.

Of course this has only led to a lot of clock watching and reluctance to work beyond stipulated hours

According to the King’s fund, there are 30,000 consultants whose salaries have increased by almost 36% from 2001. As per the new agreement the consultants will have to work for a total of 40 hours a week. They earn extra money while working more sessions.

'So far, it is less clear what the service and patients have got out of the deal beyond greater transparency of consultant workloads,' the report said.


'"/>




Page: 1

Related medicine news :

1. An urgent need for prison reforms: California!
2. Stagnant IMR calls for improved health sector reforms
3. HIV infected patients can travel safely abroad
4. New vaccine helps allergy and asthma patients
5. Doctors operate upon patients in candlelight- latest from the quake scene
6. New vaccine helps allergy and asthma patients
7. Are cancer patients being taken for a ride?
8. Alternative medicine more popular among HIV positive patients
9. ATG useful in transplant patients as substitute for steroids
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Distraction therapy found very effective in postoperative patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NHS reforms not benefiting patients

(Date:7/29/2015)... , ... July 29, 2015 , ... Indiana is known ... is also the home of Zerorez Indianapolis, which plans to expand across the state. ... “2015 is our second full year in business and we should double our first ...
(Date:7/29/2015)... FL (PRWEB) , ... July 29, 2015 , ... ... Dermatology, is the first dermatologist in Sarasota to be chosen by the manufacturer ... , “Kybella offers the first injectable, non-invasive way to treat and eliminate double ...
(Date:7/29/2015)... ... July 29, 2015 , ... Hernia repairs have always been common and routine ... by the National Center for Health Statistics indicates that more than five million ... reported annually. While the only effective treatment for a hernia is surgery, only about ...
(Date:7/29/2015)... ... July 29, 2015 , ... ITW Dynatec, ... In her role, Powers is responsible for driving growth and innovation across ITW ... “Gina’s track record as an effective leader within the ITW community speaks for ...
(Date:7/28/2015)... , ... July 29, 2015 , ... ... executives, doctors, lawyers and other A-Listers, has evolved into a world class millionaires ... a Millionaire strives to match successful and attractive people seeking real, meaningful and ...
Breaking Medicine News(10 mins):Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 2Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3Health News:Meet a Millionaire Announces It’s Not a Sugar Daddy Site, It’s a True Millionaires Club 2
... from the patient,s leg are used to strengthen weak muscles that can ... ... 2009 -- Urologists at Beaumont Hospital ( http://www.beaumonthospitals.com ) are first in ... stem cells through a research study. The stem cells are used to ...
... portion of spring promotion WHITE PLAINS, N.Y., March 10 ... a partnership with Gap Inc. through its Give & ... research, patient education and support initiatives.LLS is one of ... during the upcoming Give & Get promotion. For three ...
... The Caryl Ehrlich Program Changes Lives with 10-Sessions for ... alternative to dieting that does work. It,s called The ... people view weight loss entirely. Instead of countless diets, ... change habits of thought and word to lose weight ...
... LLC, the industry,s premier health information exchange, ... to President and Chief Operating Officer.(Logo: ... role in health care reform, leveraging our ... health quality and efficiency," said Julie Klapstein, ...
... $3.7 Million Impact on D.C. Breast HealthWASHINGTON, March 10 ... of Susan G. Komen for the Cure(R) joined the Hon. ... the Italian Embassy to officially kick off registration for the ... Cure(R), which will be held on the Washington, D.C. National ...
... MIAMI, March 10 Karen Peterson has been ... VITAS Innovative Hospice Care(R), one of the nation,s ... position, Peterson will have oversight for the interdisciplinary ... programs located throughout the country.Peterson most recently was ...
Cached Medicine News:Health News:Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence 2Health News:Gap Inc., The Leukemia & Lymphoma Society Encourage Shoppers to Support Cancer-Fighting Programs 2Health News:Behavioral Approach to Weight Loss 2Health News:Availity Promotes Russ Thomas to President and Chief Operating Officer 2Health News:D.C. Mayor Fenty, Italian Ambassador Help Announce First-Ever Susan G. Komen Global Race for the Cure(R) 2Health News:D.C. Mayor Fenty, Italian Ambassador Help Announce First-Ever Susan G. Komen Global Race for the Cure(R) 3Health News:D.C. Mayor Fenty, Italian Ambassador Help Announce First-Ever Susan G. Komen Global Race for the Cure(R) 4Health News:VITAS Innovative Hospice Care(R) Names Karen Peterson Vice President and Chief Nursing Officer 2
(Date:7/29/2015)... -- According to a new market research ... & Forecasts (2015-2020) , published by Mordor Intelligence, the ... billion by the end of 2020, with ... accounting for more than 36% of the global market ... to grow at a CAGR of 44.6% during the ...
(Date:7/28/2015)... 2015  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, today reported net income for the ... per diluted share.  Adjusted net income on a non-GAAP ... compared to $0.88 per diluted share in the prior ... income was $5.09 per diluted share, which included a ...
(Date:7/28/2015)... Scripts Holding Company (Nasdaq: ESRX ) announced 2015 ... of $600.1 million, or $0.88 per diluted share.  Adjusted ... were $1.44 for the second quarter. 1  ... are validating the need for size and scale," said ... matters most is how that size and scale is ...
Breaking Medicine Technology:New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
... NEW YORK, Oct. 6, 2011 ... research report is available in its ... Therapeutics Market to 2017 - Patent ... Negatively Impact Dyslipidemia Market Value ...
... Calif. and BARCELONA, Spain, Oct. 6, 2011 ... and Grupo Ferrer International, S.A., announced today that they ...  ADASUVE is Alexza,s lead program, based on the company,s ... is a leading pharmaceutical company in Europe with extensive ...
Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 2Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 3Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 4Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 5Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 6Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America 7
Sinus Trocar and Cannula, 4 mm...
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve....
An air-based corneal esthesiometer that can stimulate subthreshold at corneal apex in normals. Has use in determining corneal physiology, healing, etc. May have application to the measurement of norm...
Kelly Punches...
Medicine Products: